Signet Therapeutics gets FDA IND approval for sigx1094 in diffuse gastric cancer
Signet Therapeutics, a pioneering biotech company, has achieved a significant milestone with the US Food and Drug Administration (FDA)’s Investigational New Drug (IND) approval of its drug candidate, sigx1094, for the treatment of diffuse gastric cancer (DGC). This marks the introduction of the first targeted therapy for DGC, a disease currently lacking effective treatment options. […]